|
Momelotinib Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: OJJAARA
Pipeline
Early 1: 1Phase 1: 1Phase 1/2: 1
Top Sponsors
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
- M.D. Anderson Cancer Center1
- Janssen Research & Development, LLC1
Indications
- Cancer3
- Chronic Neutrophilic Leukemia1
- Myeloproliferative Overlap Neoplasms1
- Myeloid Leukemia1
- Myelofibrosis1
Duarte, California1 trial
Baltimore, Maryland1 trial
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early 1
Houston, Texas1 trial
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
MD Anderson Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.